R&D Supervisor, Genetic Sciences
Thermo Fisher Scientific
Lab leaders are under pressure to adopt AI and automation, and most of that pressure is well-founded. When properly implemented, AI and robotic systems, including automated polymerase chain reaction (PCR) workflows, can reduce manual variability, ease workflow bottlenecks, and produce high-quality data. When integration runs ahead of the science underneath it, new tools can introduce errors and slow down the work they were meant to accelerate.
In genetic analysis, credibility is built on reproducibility. New instruments and software continue to enter the market with the promise of faster and higher-quality results. However, the variable that is most often overlooked is also the most consequential: the reagents and consumables that influence every reaction. Real-time PCR (qPCR) assays, master mixes, primers, probes, plates, seals, and tips quietly determine whether a workflow can be trusted, especially as new platforms enter the market with the promise of faster, cleaner results.
When labs chase speed without stabilizing the basics, they risk building sophisticated workflows on unstable foundations. AI and automation cannot reduce variability on their own. They depend on consistent consumables, robust chemistry, and strong traceability. Without that foundation, small issues can scale into batch-level failures. Labs that want to succeed with new technology must first invest in analytically validated reagents that make that technology trustworthy.
Automation amplifies everything
Automation can generate more data faster, but it can also scale small problems into larger ones when inputs from genetic analysis experiments, such as assay design, reagent chemistry, and consumables, are inconsistent. For example, a master mix that performs well in a manual benchtop workflow may behave differently after sitting on an automated deck for an extended period. If evaporation, temperature exposure, or incomplete mixing shifts reaction concentration in only a subset of wells, the result may not appear as a complete run failure. Instead, the lab may see subtle threshold cycle (Ct) shifts, increased well-to-well variation, or edge effects that are difficult to trace after the run is complete. In high-throughput qPCR, reproducibility often depends less on the thermal cycler than on reagent performance and reaction assembly.
Automation without consumable consistency across assays and master mixes does not always save time. Rather, it shifts time from pipetting to troubleshooting. Before scaling, labs should evaluate whether assays, master mixes, and consumables can perform under real automated conditions (e.g., hold times, ambient exposure, and mixing steps); not just under ideal bench conditions.
Consumable quality is critical
Multiplex qPCR leaves almost no margin for uncontrolled variability, which makes consumable consistency across qPCR assay design and chemistries an especially important consideration in genetic analysis labs. When several targets are amplified in a single reaction, noise sources, such as baseline instability, spectral bleed, and inconsistent fluorescence transmission, can compete with the real signal. The result is curves that are difficult to interpret and translate into action.
Consumables that perform consistently lot-to-lot, with low-binding surfaces, robust sealing, and low-background optics, paired with multiplex-stable master mixes, give labs fewer reruns and cleaner target differentiation. The practical step is to qualify every new lot under the conditions where it will actually run, including hold times, mixing steps, and full multiplex panels, before releasing it into production. That requires evaluating plates, seals, and tips for autofluorescence, adsorption, and lot-to-lot optical consistency, not just for sterility or general compatibility.
What your controls aren’t saying
Common assumptions about consumable quality create blind spots that can become dangerous at scale. Three are worth calling out. First, “sterile” does not automatically mean nuclease-free or DNA-free. These certifications cover different things, and a label that satisfies a procurement specification may not satisfy a sensitive amplification reaction. Second, passing controls does not guarantee an entire plate is unaffected. Controls can miss edge effects; low-input loss and mild inhibition can still distort results in target wells. Third, master mixes are not interchangeable. Formulation and lot variation change efficiency, inhibitor tolerance, and multiplex behavior, sometimes in ways that only surface after a method transfer.
A practical step that genetic analysis labs can take is to test consumables under worst-case conditions: low input, edge wells, and extended hold times. That is closer to how an automated workflow actually behaves.
AI is not a guarantee
AI has the potential to add real value in genetic analysis workflows, but only when it sits on top of consistent physical inputs and good metadata. It does not replace the need for widely used consumables and traceability.
AI has the potential to flag issues early, including Ct drift, edge effects, and unusual amplification curves. It tracks trends over time and links problems to reagent lots, instruments, or staging conditions. However, the dependency runs in both directions. AI-driven quality monitoring is only as good as the data it receives. If consumables introduce uncontrolled variability through inconsistent optics, adsorption losses, or leachables, AI may detect symptoms without identifying root causes. Even worse, it may normalize drift if the baseline itself is unstable. The difference between a useful flag and a misleading one usually comes down to whether the lab can trace what changed.
Consider this scenario: A lab uses AI to monitor plate-to-plate performance, and the system flags a subtle upward Ct trend. With appropriate traceability, meaning lot numbers for plates, seals, master mix, and tips linked to each run, the team traces the issue to a new consumable lot with higher autofluorescence. Without that metadata, the trend is visible but unexplainable. The model can flag that something is wrong, but it cannot explain it.
The implication: traceability is a workflow discipline problem, not a software problem. Scientists need to build traceability into every run (e.g., link reagent lots, consumable lots, staging conditions, and instrument IDs to results). Without this metadata for AI to consume, there is no AI-driven quality monitoring.
Get the foundation, then scale
The real innovation ahead is not just smarter software or technology. It is robust assay design, reagent chemistry, and consumables designed for automated workflows: stable at room temperature, tolerant to inhibitors, and consistent in multiplex performance. Better traceability, with reagents and labware tracked by lot and linked to QC data, supports more unattended runs, fewer failures, and faster troubleshooting when something does go wrong.
AI and automation can move genetic analysis forward, but only when the underlying workflow is already controlled. The lab of the future will not be defined by how much human judgment it removes. It will be defined by how well it preserves that judgment with better data, better context, and fewer avoidable sources of variation. That starts with unglamorous work: qualifying consumable lots, documenting reagent and labware changes, stress-testing chemistries on automated decks, and making traceability part of every run. These are not side details. They are the foundation that determines whether AI-enabled genetic analysis produces insight or simply scales uncertainty.
